Rznomics Seeks WHO Drug Name for Cancer Gene Therapy

Industry Insights from Next Move Strategy Consulting

Rznomics has taken a significant step toward globalizing its cancer gene therapy pipeline by applying to the World Health Organization (WHO) for an International Nonproprietary Name (INN) for its lead candidate, RZ-001. The Korean biotechnology company stated that this move is aimed at strengthening the drug’s international positioning and supporting future global development and partnering efforts.

The application reflects Rznomics’ intent to align RZ-001 with international pharmaceutical standards, enabling consistent identification across regulatory authorities, healthcare systems, and global markets.

Establishing a Global Identity for RZ-001

An INN is a standardized, nonproprietary name assigned by the WHO to active pharmaceutical substances, ensuring clarity and uniform recognition worldwide. Rznomics noted that the proposed name for RZ-001 was crafted to represent the therapy’s underlying mechanism and molecular components, underscoring its status as a first-in-class treatment approach.

RZ-001 was developed using Rznomics’ proprietary RNA-editing platform based on trans-splicing ribozyme technology. This platform serves as the foundation for the company’s gene therapy strategy and differentiates the program within the oncology landscape.

Clinical Progress Across Multiple Cancer Indications

According to the company, RZ-001 has received investigational new drug approvals in both South Korea and the United States. The therapy is currently being evaluated in clinical trials targeting glioblastoma and hepatocellular carcinoma (HCC), two cancer indications with high unmet medical needs.

Rznomics recently presented interim data from an ongoing phase 1/2a glioblastoma trial at the ESMO Asia Congress held on December 5. The company highlighted a favorable safety profile based on the data shared at the event.

In addition, Rznomics plans to disclose interim results from its phase 1b/2a hepatocellular carcinoma trial in the first half of the coming year, signaling continued clinical momentum across its oncology pipeline.

Regulatory Milestones and Accelerated Pathways

Further strengthening the development outlook for RZ-001, the U.S. Food and Drug Administration has granted the therapy orphan drug designation as well as fast track status for both glioblastoma and hepatocellular carcinoma. These regulatory designations are intended to support the development of therapies addressing serious conditions and may help expedite the review process.

Next Move Strategy Consulting View: Cancer Drug Market Outlook

According to Next Move Strategy Consulting, advancements such as Rznomics’ RZ-001 reflect a broader shift within the Cancer Drug Market toward precision-driven and gene-based therapies. The growing focus on innovative platforms, global regulatory alignment, and accelerated development pathways is reshaping how oncology drugs are positioned for international markets.

As more biotech companies pursue first-in-class therapies and seek early global recognition through mechanisms like WHO INN assignments, the cancer drug market is expected to see increased emphasis on differentiation, regulatory readiness, and cross-border collaboration.

Strengthening Global Development Strategy

By pursuing an INN designation at this stage, Rznomics is reinforcing its strategy to establish RZ-001 as a globally recognizable cancer gene therapy candidate. The move supports clearer communication with regulators, partners, and clinical stakeholders as the program advances through development.

With ongoing trials, upcoming data disclosures, and regulatory support already in place, RZ-001 continues to represent a central pillar in Rznomics’ efforts to expand its presence in the global oncology landscape.

Source: Korea Biomedical Review

Prepared by: Next Move Strategy Consulting